DC
LXRX icon

Diametric Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Diametric Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,841
Closed -$106K – 596
2026
Q1 		$106K Buy
+67,841
New +$98.6K 0.03% 416
2023
Q3 		– Sell
-13,988
Closed -$32K – 389
2023
Q2 		$32K Buy
+13,988
New +$37.1K 0.01% 316

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Diametric Capital's LXRX Position: Q2 2026 in Review

Diametric Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 67,841 shares — an estimated $106K sold.

Diametric Capital first reported a position in LXRX in Q2 2023 and held it in 2 quarters. The position peaked at $106K in Q1 2026. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Diametric Capital reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 67,841 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $106K.
  • Diametric Capital first reported a position in Lexicon Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Diametric Capital's Lexicon Pharmaceuticals position peaked at $106K in Q1 2026.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.